Time filter

Source Type

Ping P.,Shanghai Institute of Andrology | Zhu W.-B.,Central South University | Zhang X.-Z.,Zhejiang Institute | Yao K.-S.,Zhejiang Institute | And 3 more authors.
Asian Journal of Andrology | Year: 2010

Sperm banking can preserve male fertility effectively, but the current conditions of sperm cryopreservation in China have not been investigated. This retrospective investigation was based on data collected at multiple centres in China from January 2003 to December 2008. The collected data included urogenital history, indication for cryopreservation, semen parameters, use rate, type of assisted reproductive technique (ART) treatment and pregnancy outcome. The study population included 1 548 males who had banked their semen during the study period at one of the clinics indicated above. Approximately 1.9% (30/1 548) of the cryopreserved semen samples were collected from cancer patients; about 88.8% (1 374/1 548) of the patients had banked their semen for ART and 8.6% (134/1 548) had a male infertility disease (such as anejaculation, severe oligozoospermia and obstructive azoospermia). The total use rate of cryopreserved semen was 22.7% (352/1 548), with 119 live births. The cancer group use rate was 6.7% (2/30), with one live birth by intracytoplasmic single sperm injection (ICSI). The ART group use rate was 23.2% (319/1 374), with 106 live births. The reproductive disease group use rate was 23.1% (31/134), with 12 live births. The semen parameters in each category varied; the cancer patient and infertility disease groups had poor semen quality. In vitro fertilization (IVF) and ICSI were the most common ART treatments for cryopreserved sperm. Semen cryopreservation as a salvage method is effective, but in many conditions it is underutilized, especially in cancer patients. Lack of awareness, urgency of cancer treatment and financial constraints are the main causes of the low access rate. The concept of fertility preservation should be popularized to make better use of this medical service in China. © 2010 AJA, SIMM & SJTU All rights reserved. Source

Lui C.,Shanghai University | Cui X.-G.,Shanghai University | Wang Y.-X.,Shanghai Institute of Andrology | Xu D.-F.,Shanghai University
Journal of Assisted Reproduction and Genetics | Year: 2010

Purpose: To investigate the relationship between oxytocin (OT) and male infertility, serum OT baseline concentration and oxytocin receptor (OTR) gene expression in fertile and infertile men were investigated. Methods and patients: Twenty obstructive azoospermia patients, twenty five idiopathic asthenozoospermia patients, twenty idiopathic oligozoospermia patients and twenty healthy subjects were taken into consideration. Serum OT baseline concentration was determined by radioimmunoassay. Moreover, serum concentration of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone (T) were determined by chemoluminescence to evaluate the correlation with OT. OTR gene promotor and OTR mRNA expressions were determined by polymerase chain reaction and reverse transcriptase-polymerase chain reaction, respectively. OTR protein expression was also performed by Western Blot. Results: Serum OT baseline concentrations in infertile groups were significantly higher than in fertile group (F0.05/2(2,82)=8.29, p<0.001). Serum baseline concentration of OT was not correlated with that of LH, FSH and T. There was no significant difference in gene sequences of OTR gene promotor and OTR mRNA when comparing infertile patients with fertile. Human OTR was in the form of oligomers and monomers, and the oligomers were in the majority containing tetramers and hexamers. Monomer expression was significantly higher in idiopathic asthenozoospermia and idiopathic oligozoospermia than that in obstructive azoospermia and control group (F0.05/2(2,82)=115.50, p<0.001). There was no significant difference in oligomer expression between different groups, but 20% of idiopathic asthenozoospermia cases showed a decrease. Conclusions: Significantly different OT baseline concentrations and OTR expressions between fertile and infertile men strongly suggest that OT/OTR system is likely to be linked with male infertility, providing new insights into the pathogenesis and treatment of male infertility. © 2010 Springer Science+Business Media, LLC. Source

Wang X.-B.,Shanghai Institute of Andrology | Hu H.-L.,Shanghai Institute of Andrology | Liu Y.,Shanghai Institute of Andrology | Cao X.-R.,Shanghai Institute of Andrology | And 3 more authors.
Journal of Shanghai Jiaotong University (Medical Science) | Year: 2012

Objective: To analyse karyotype of chromosome in patients with infertility and sperm donors, and explore its clinical significance. Methods: A total of 967 infertile patients (infertility group) and 3 184 semen donors (donor group) were selected for analysis of karyotype of chromosome, and the incidence and types of abnormal karyotypes were compared between two groups. Results: The incidence of abnormal karyotypes in infertility group was significantly higher than that in donor group (14.06% vs 3.39%, P<0.01). The main type of abnormal karyotype in infertility group was non-polymorphic chromosomal abnormalities, whose incidence was significantly higher than that in donor group (9.62% vs 0.25%, P<0.05). The main type of abnormal karyotype in donor group was polymorphic chromosomal abnormalities, whose incidence was not significantly different from that in infertility group (3.14% vs 4.44%, P>0.05). Besides, two abnormal karyotypes [46, XY, t(3; 12)(p23; q24) and 46, XY, inv(20)(p13; q13.1)] were first reported worldwide in infertility group. Conclusion: Chromosome non-polymorphism abnormalities is one of the major causes for male infertility, and karyotype analysis for infertile patients and sperm donors is of great significance to reduce birth defects. Source

Yang Y.,Shanghai JiaoTong University | Yang Y.,Shanghai Institute of Andrology | Hu J.-L.,Shanghai JiaoTong University | Hu J.-L.,Shanghai Institute of Andrology | And 12 more authors.
Journal of Urology | Year: 2011

Purpose: We prospectively compared clinical response and penile color duplex ultrasound results of oral tadalafil 20 mg plus low dose intracavernous injection of vasoactive agents with those of intracavernous injection and oral tadalafil 20 mg alone. We also observed the best approach to facilitate penile color duplex ultrasound and that most preferred by patients. Materials and Methods: All 56 patients with erectile dysfunction underwent penile color duplex ultrasound 3 times at an interval of at least 1 week using different pharmacological induction methods, including tadalafil mode (20 mg tadalafil), intracavernous injection mode (30 to 60 mg papaverine) and mixed mode (15 mg papaverine plus 20 mg tadalafil). Ultrasound parameters included peak systolic and end diastolic velocity, resistance index and acceleration time. Clinical response was assessed by the erection hardness score. Patient preference was determined when all tests were finished. Results: For penile color duplex ultrasound parameters no significant difference was observed between intracavernous injection and mixed modes. However, for tadalafil mode peak systolic velocity of the 2 cavernous arteries measured 15 minutes after induction were significantly lower than for intracavernous injection and mixed modes. Also, acceleration time of the right cavernous artery measured 5 minutes after induction and left cavernous artery measured 15 minutes after induction in tadalafil mode were significantly shorter than those in intracavernous injection and mixed modes. No severe side effect occurred in tadalafil and mixed modes but 2 patients experienced priapism in intracavernous injection mode. Of the patients 55.4% preferred tadalafil mode, an incidence significantly higher than intracavernous injection (16.1%) and mixed (28.5%) modes. Conclusions: Oral tadalafil plus low dose vasodilator led to a significantly better clinical response than high dose vasodilator. Penile color duplex ultrasound parameters showed no difference between the 2 modes. Thus, this mixed mode emerges as a possible alternative to high dose vasodilator injection. © 2011 American Urological Association Education and Research, Inc. Source

Discover hidden collaborations